FIELD: pharmacology.
SUBSTANCE: pharmaceutical comprises of a recombinant mistletoe lectin including the amino acid sequences ID SEQ No. 1 and SEQ ID No. 4. The group of inventions also relates to a pharmaceutical composition.
EFFECT: effectiveness of treatment is increased, increasing the survival of patients.
12 cl, 1 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT MISTLETOE LECTIN AND USE THEREOF AS ADJUVANT | 2012 |
|
RU2664458C2 |
| METHOD OF TREATING MELANOMA IN VIVO | 2023 |
|
RU2824428C2 |
| METHOD FOR ADJUVANT THERAPY OF CANCER | 2013 |
|
RU2640180C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATMENT WITH ANTIBODIES AGAINST VEGF | 2004 |
|
RU2519669C2 |
| CONJUGATES FOR TREATING MESOTHELIOMA | 2009 |
|
RU2502518C2 |
| ANTIBODY, STOPPING OR RETARDING TUMOUR GROWTH (VERSIONS), METHOD OF SUPPRESSING TUMOUR GROWTH, METHOD OF DIAGNOSING MALIGNANT LESIONS | 2011 |
|
RU2440142C1 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
